fexapotide triflutate

I posted here a year ago about this new drug. Myself and others had reservations regarding the trials that were done. Seems the company that makes the drug has applied to the FDA for use in the USA. There is a short but interesting article at medscape. Here is an exerpt from the article.

By stimulating a variety of molecular pathways, fexapotide selectively causes loss of prostate glandular epithelial cell integrity, with subsequent decompression of the urethral lumen.

Fexapotide treatment was associated with significantly greater improvement in BPH Symptom Score at 365 days or last follow-up (median, 5.2 points vs. 3.0 points with placebo), according to the single January 29 World Journal of Urology online report on the four studies. Jimjames and I discussed this a while back. Its odd that the plecebo seemed to work well also

The incidence of spontaneous acute urinary retention within 3 years was significantly lower with fexapotide (1.08%) than with placebo (5.63%), as was the incidence of newly diagnosed prostate cancer at 4 years (1.1% vs. 5.3%).

In the crossover studies, the 3-year incidence of BPH surgery was far lower among men who received fexapotide (8.08%) than among those treated with other BPH medications (27.85%).

I didn't post the whole article due to copy write and this website rules. Accounts at medscape are free if you'd like to see the whole article

0 likes, 19 replies